{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:11:24Z","timestamp":1791411084259,"version":"4.3.3"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.cllc.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T11:47:58Z","timestamp":1581335278000},"page":"e349-e354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study"],"prefix":"10.1016","volume":"21","author":[{"given":"Tianle","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinluan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1105-8131","authenticated-orcid":false,"given":"Yinbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.02.006_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jamaoncol.2017.5190","article-title":"Treatment of advanced non-small cell lung cancer in 2018","volume":"4","author":"Doroshow","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jtho.2018.01.002","article-title":"Progress in the management of advanced thoracic malignancies in 2017","volume":"13","author":"Ferrara","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib3","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.02.006_bib4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced non squamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.02.006_bib5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/annonc\/mdz109","article-title":"How to make the best use of immunotherapy as first-line treatment for advanced\/metastatic non-small-cell lung cancer","volume":"30","author":"Peters","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2020.02.006_bib7","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib8","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib10","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib11","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/annonc\/mdw163","article-title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A\u00a0prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2020.02.006_bib14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","article-title":"Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas","volume":"3","author":"Drilon","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2020.02.006_bib15","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.lungcan.2016.09.002","article-title":"Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma","volume":"101","author":"Song","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.02.006_bib17","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2020.02.006_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib19","doi-asserted-by":"crossref","first-page":"29230","DOI":"10.1074\/jbc.M703461200","article-title":"Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting","volume":"282","author":"Plaza-Menacho","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cllc.2020.02.006_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1126\/scitranslmed.aah6144","article-title":"Drugging the catalytically inactive state of RET kinase in RET rearranged tumors","volume":"9","author":"Plenker","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cllc.2020.02.006_bib21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl","key":"10.1016\/j.cllc.2020.02.006_bib22","first-page":"102","article-title":"A\u00a0phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers","volume":"36","author":"Alexander","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.02.006_bib23","author":"Drilon"},{"key":"10.1016\/j.cllc.2020.02.006_bib24","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). ASCO 2019","volume":"37","author":"Gainor","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420300218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420300218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:09:45Z","timestamp":1761505785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420300218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1525730420300218"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.02.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}